Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study
- PMID: 10030250
- DOI: 10.1016/s0360-3016(98)00413-1
Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study
Abstract
Purpose: To report the results of a Phase II study of hyperfractionated craniospinal radiation therapy, with and without adjuvant chemotherapy for primitive neuroectodermal brain tumors (PNETs) and malignant ependymomas.
Methods and materials: Newly diagnosed PNET or malignant ependymomas were treated with hyperfractionated craniospinal radiation therapy. The primary tumor site was treated to a dose of 72 Gy, with 30 Gy given to the rest of the craniospinal axis. The fraction size was 1.0 Gy, given twice a day. Patients with poor risk factors also received adjuvant chemotherapy with CCNU, cisplatin, and vincristine. Patients had follow-up for survival, time to tumor progression, and patterns of relapse.
Results: A total of 39 patients (21 males/18 females) were treated between March 12, 1990 and October 29, 1992. The median age was 16 years (range 3-59 years). Tumor types included 25 medulloblastomas, 5 pineoblastomas, 5 cerebral PNETs, 1 spinal cord PNET, and 3 malignant ependymomas. Twenty cases were staged as poor-risk and received adjuvant chemotherapy following radiation. Three-year progression-free survival (PFS) was 60% and 63% for poor-risk and good-risk patients, respectively. Overall 3-year survival for these groups was 70% and 79%, respectively. For the 25 patients with medulloblastoma, there were 16 good-risk and 9 poor-risk patients. Three-year PFSs were 63% and 56%, respectively. The 5-year survival for good-risk medulloblastoma was 69% with 43.7% of these patients having failures outside the primary site.
Conclusions: Survival in patients with good-risk medulloblastoma was no better than that seen in previous studies with single-fraction radiation, and the rate of failure outside the primary site is excessive. Those with poor-risk features had comparable survival to that seen in patients with good risk factors, but these patients were treated with chemotherapy, and the role that hyperfractionated radiation played in their outcome is uncertain.
Similar articles
-
Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.Pediatr Neurosurg. 1996 Oct;25(4):174-81. doi: 10.1159/000121120. Pediatr Neurosurg. 1996. PMID: 9293544
-
Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: early results of a pilot study.Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):431-8. doi: 10.1016/0360-3016(94)90067-1. Int J Radiat Oncol Biol Phys. 1994. PMID: 8276658
-
Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy.Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):863-71. doi: 10.1016/j.ijrobp.2014.04.017. Int J Radiat Oncol Biol Phys. 2014. PMID: 24969797 Clinical Trial.
-
[Current and future strategies in interdisciplinary treatment of medulloblastomas, supratentorial PNET (primitive neuroectodermal tumors) and intracranial germ cell tumors in childhood].Strahlenther Onkol. 2001 Sep;177(9):447-61. doi: 10.1007/pl00002426. Strahlenther Onkol. 2001. PMID: 11591018 Review. German.
-
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience.Neuro Oncol. 1999 Apr;1(2):152-61. doi: 10.1093/neuonc/1.2.152. Neuro Oncol. 1999. PMID: 11554387 Free PMC article. Review. No abstract available.
Cited by
-
Emerging treatments and gene expression profiling in high-risk medulloblastoma.Paediatr Drugs. 2007;9(2):81-96. doi: 10.2165/00148581-200709020-00002. Paediatr Drugs. 2007. PMID: 17407364 Review.
-
Medulloblastoma in children: a 32-year experience from a single institution.J Neurooncol. 2008 Oct;90(1):99-103. doi: 10.1007/s11060-008-9638-x. Epub 2008 Jun 20. J Neurooncol. 2008. PMID: 18566744
-
Primary pineal tumors: outcome and prognostic factors--a study from the Rare Cancer Network (RCN).Clin Transl Oncol. 2012 Nov;14(11):827-34. doi: 10.1007/s12094-012-0869-0. Epub 2012 Aug 23. Clin Transl Oncol. 2012. PMID: 22914906
-
Medulloblastoma.Curr Treat Options Neurol. 2003 May;5(3):189-198. doi: 10.1007/s11940-003-0009-9. Curr Treat Options Neurol. 2003. PMID: 12670407
-
A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1006-11. doi: 10.1016/j.ijrobp.2008.09.019. Epub 2009 Apr 7. Int J Radiat Oncol Biol Phys. 2009. PMID: 19356859 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases